Cargando…

MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner()()

PURPOSE: Increased murine double minute 2 (MDM2) expression, independent of p53 status, is associated with increased cancer-specific mortality for men with prostate cancer treated with radiotherapy. We assessed MI-219, a small molecule inhibitor of MDM2 with improved pharmacokinetics over nutlin-3,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Felix Y., Zhang, Yu, Kothari, Vishal, Evans, Joseph R., Jackson, William C., Chen, Wei, Johnson, Skyler B., Luczak, Connor, Wang, Shaomeng, Hamstra, Daniel A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2016
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840291/ https://www.ncbi.nlm.nih.gov/pubmed/27108384 http://dx.doi.org/10.1016/j.neo.2016.01.006

Ejemplares similares

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective
por: Zhao, Yujun, et al.
Publicado: (2014)

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
por: Chopra, Harman, et al.
Publicado: (2017)

Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy
por: Foster, Corey C, et al.
Publicado: (2014)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
por: McDevitt, Michael R., et al.
Publicado: (2018)

Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
por: Qin, Jiang-Jiang, et al.
Publicado: (2017)

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer
por: Tovar, Christian, et al.
Publicado: (2011)

C-Reactive Protein Is a Poor Marker of Baseline Inflammation in Prostate Cancer and Response to Radiotherapy or Androgen Ablation
por: Jensen, Garrett L, et al.
Publicado: (2021)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer
por: Xue, Li, et al.
Publicado: (2015)

The role of mesenchymal stem cells in promoting the transformation of androgen-dependent human prostate cancer cells into androgen-independent manner
por: Cheng, Jiwen, et al.
Publicado: (2016)

Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners
por: Guo, Zhuifeng, et al.
Publicado: (2022)

Opposing effects of androgen ablation on immune function in prostate cancer
por: Tang, Shuai, et al.
Publicado: (2012)

Detection of P53 and Mdm2 in vitiligo
por: Wiwanitkit, Viroj
Publicado: (2013)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Evolution of the p53-MDM2 pathway
por: Åberg, Emma, et al.
Publicado: (2017)

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
por: Mohammad, Ramzi M, et al.
Publicado: (2009)

Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?
por: Rao, Arpit, et al.
Publicado: (2022)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner
por: Li, Ying, et al.
Publicado: (2022)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
por: Coffill, Cynthia R., et al.
Publicado: (2016)

E2F1-Dependent Oncogenic Addiction of Melanoma Cells to MDM2
por: Verhaegen, Monique, et al.
Publicado: (2011)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2
por: Yadahalli, Shilpa, et al.
Publicado: (2019)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
por: Mejía-Hernández, Javier Octavio, et al.
Publicado: (2022)

A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy
por: Jackson, William C, et al.
Publicado: (2013)

Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1
por: Zhang, Yiming, et al.
Publicado: (2021)

The RP-Mdm2-p53 Pathway and Tumorigenesis
por: Miliani de Marval, Paula L., et al.
Publicado: (2011)

Controlling the Mdm2-Mdmx-p53 Circuit
por: Waning, David L., et al.
Publicado: (2010)

Immunohistochemical detection of P53 and Mdm2 in vitiligo
por: Bakry, Ola A., et al.
Publicado: (2012)

Heterogeneous Hydration of p53/MDM2 Complex
por: Guo, Zuojun, et al.
Publicado: (2014)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX
por: Levy, Robin, et al.
Publicado: (2019)

The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f4uu6t7ggp396gnhb87bbk5ot7